Niva Bupa Health Insurance Company Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 6 Aug 2026 | Insurance | Market Cap: ₹16.2K Cr
Overall growth in Q3 was 31%, and 26% for the first 9 months, indicating strong upward momentum. The company targets a Return on Equity (ROE) in the high teens within the next two financial years, indicating growth in profitability.
From Niva Bupa Health Insurance Company Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹82.6
Market Cap
₹16.2K Cr
P/E Ratio
92.9
How does Niva Bupa Health Insurance Company Ltd rank in Insurance?
Compare Niva Bupa Health Insurance Company Ltd against every Insurance company this quarter on revenue, margins and earnings-call signals.
Niva Bupa Health Insurance Company Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.1K Cr, net profit ₹345 Cr.
Full financials →📊 Revenue & Sales Performance
- →Overall growth in Q3 was 31%, and 26% for the first 9 months, indicating strong upward momentum.
- →New business growth was particularly robust at 46% in Q3 and 30% YTD, driving market share gain from 9.6% to 10.2%.
- →Key channels show strong performance: agency grew 43% in Q3 and 32% YTD; banca NBFC channel grew 27.5% in Q3 and 19% YTD.
- →Digital direct channel demonstrates exceptional growth at 70% for Q3 and 49% YTD.
- →Tailwinds from GST and awareness campaigns are sustaining healthy volume and value growth, with January trends continuing positively.
- →The company forecasts continued growth supported by these channels and sustained product traction, like the Reassure 3.0 product.
- →Medium-term outlook aims for enhancing profit margins with ROE targeted in the high teens within two years, supporting profitable growth.
📈 Profitability & Margins
- →The company targets a Return on Equity (ROE) in the high teens within the next two financial years, indicating growth in profitability.
- →Profit after tax under IFRS increased by 74% year-to-date compared to the previous year, showing strong earnings growth momentum.
- →Combined Operating Ratio (COR) has improved due to better expense management, despite a slight increase in loss ratio.
- →The company expects continued sustainable growth through disciplined underwriting, renewal upselling, and cost management initiatives.
- →Investment yield is steady (7.3% annualized for 9 months), supporting investment income.
- →Operating efficiency initiatives and capital allocation are aligned to balance growth and strengthen return metrics.
- →Pricing discipline with annual single-digit price increases aims to manage inflation impacts without causing customer lapses.
- →Overall, profitability and earnings are expected to grow steadily, driven by scale, cost efficiencies, and prudent portfolio management.
🏗️ Capital Expenditure Plans
- →No specific mention of current or future capex or strategic capital investments in the provided transcript.
- →The discussion primarily focuses on operational aspects such as pricing discipline, claims management, product development, underwriting sophistication, and digital health services.
- →Capital-related comments are limited to maintaining a strong solvency ratio (2.49) and alignment of capital allocation to support growth and strengthen return metrics.
- →Vishwanath Mahendra highlighted plans for medium-term ROE improvement but did not specify new capital expenditure.
- →The company is managing capital prudently with an eye on profitability, claims ratios, and operating leverage, rather than emphasizing large new investments.
- →Capital raising is indicated as planned but not detailed; solvency levels are healthy to support ongoing business growth.
💰 Fundraising & Capital Structure
- →Regarding solvency and capital, Vishwanath Mahendra mentioned that solvency dipped from 300+ to 249, possibly due to 1/N accounting.
- →The company expects Q4 IGAAP profits to be strong and sees no solvency concerns.
- →Ankur Kharbanda confirmed multi-year policies stability and no major change impacting solvency.
- →Vishwanath stated that their plan to raise capital is on track, and they are comfortable with the current solvency level (2.49).
- →No explicit mention of a new or upcoming fundraising through debt or equity in the provided transcript.
- →The company is focusing on maintaining growth and profitability while keeping solvency strong without signaling immediate capital raising.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Niva Bupa Health Insurance Company Ltd Q3 FY26 results?
Overall growth in Q3 was 31%, and 26% for the first 9 months, indicating strong upward momentum. The company targets a Return on Equity (ROE) in the high teens within the next two financial years, indicating growth in profitability.
What is Niva Bupa Health Insurance Company Ltd share price analysis?
Niva Bupa Health Insurance Company Ltd currently shows a neutral. The stock trades at a P/E of 92.9 with a market cap of ₹16,188 Cr. Investors should review the full earnings analysis for detailed insights.
Is Niva Bupa Health Insurance Company Ltd planning capital expenditure?
No specific mention of current or future capex or strategic capital investments in the provided transcript.
Keep Niva Bupa Health Insurance Company Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.